• Molecular NameBetahistine
  • SynonymNA
  • Weight136.198
  • Drugbank_IDN/A
  • ACS_NO5638-76-6
  • Show 3D model
  • LogP (experiment)0.68
  • LogP (predicted, AB/LogP v2.0)0.62
  • pkaN/A
  • LogD (pH=7, predicted)-2.01
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.87
  • LogSw (predicted, AB/LogsW2.0)497.75
  • Sw (mg/ml) (predicted, ACD/Labs)134.66
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA24.92
  • StatusN/A
  • AdministrationN/A
  • PharmacologyAn antivertigo drug. It is commonly prescribed to patients with balance disorders or to alleviate vertigo symptoms associated with Ménière's disease.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTo 2-(2-aminoethyl)pyridine and 2-pyridylacetic acid
  • Half life3~4 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A